Proactive Investors - Run By Investors For Investors

Alliance Pharma bolsters board with addition of two experienced non-execs

Jo Le Couilliard spent much of her career at GSK, while Richard Jones is an ex-investment banker and the current CFO of AIM-listed Mereo Biopharma
board room
Le Couilliard and Jones will join the board on 1 January

Speciality pharma group Alliance Pharma PLC (LON:APH) has appointed two new non-executive directors to its board.

Alliance said the appointments of Jo Le Couilliard and Richard Jones will add further international business experience and capital markets expertise.

READ: Alliance happy with two-pronged strategy

Le Couilliard spent most of her career at FTSE 100 drugmaker GlaxoSmithKline PLC (LON:GSK), while former investment banker Jones is the current chief financial officer of Mereo Biopharma Group PLC (LON:MPH).

Both directors qualified as accountants at Big Four accounting firm PricewaterhouseCoopers (PwC).

“I am delighted to welcome Jo and Richard to Alliance's board,” said chairman David Cook.

“They bring a huge breadth of relevant and varied experience to Alliance. Jo's extensive experience at GSK included a senior sales and marketing position in Asia Pacific, which represents Alliance's fastest growing region.

“Richard, from his work as an investment banker and as a financial executive, brings a depth of relevant capital markets experience. I look forward to their contribution to the company's ongoing development into a leading international healthcare business.”

Alliance shares were flat at 67.2p in early deals on Monday.

View full APH profile View Profile

Alliance Pharma PLC Timeline

January 21 2019

Related Articles

February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use